{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T07:30:38Z","timestamp":1786779038256,"version":"build-2736575974"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2013,11,28]],"date-time":"2013-11-28T00:00:00Z","timestamp":1385596800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1007\/s11096-013-9881-x","type":"journal-article","created":{"date-parts":[[2013,11,27]],"date-time":"2013-11-27T04:39:22Z","timestamp":1385527162000},"page":"256-260","source":"Crossref","is-referenced-by-count":4,"title":["Weaning from intravenous prostanoids and normalization of hemodynamics by long-term imatinib therapy in severe idiopathic pulmonary arterial hypertension"],"prefix":"10.1007","volume":"36","author":[{"given":"Rudolf","family":"Speich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Treder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Domenighetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars C.","family":"Huber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Ulrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,11,28]]},"reference":[{"key":"9881_CR1","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1172\/JCI24838","volume":"115","author":"RT Schermuly","year":"2005","unstructured":"Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth M, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest. 2005;115:2811\u201321.","journal-title":"J Clin Invest"},{"key":"9881_CR2","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1164\/rccm.200707-1037OC","volume":"178","author":"F Perros","year":"2008","unstructured":"Perros F, Montani D, Dorfmuller P, Durand-Gasselin I, Tcherakian C, Le Pavec J, et al. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2008;178:81\u20138.","journal-title":"Am J Respir Crit Care Med"},{"key":"9881_CR3","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJMc051946","volume":"353","author":"HA Ghofrani","year":"2005","unstructured":"Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med. 2005;353:1412\u20133.","journal-title":"N Engl J Med"},{"key":"9881_CR4","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1164\/rccm.201001-0123OC","volume":"182","author":"HA Ghofrani","year":"2010","unstructured":"Ghofrani HA, Morrell NW, Hoeper MM, Olschewski H, Peacock AJ, Barst RJ, et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med. 2010;182:1171\u20137.","journal-title":"Am J Respir Crit Care Med"},{"key":"9881_CR5","doi-asserted-by":"crossref","unstructured":"Hoeper MM, Barst RJ, Bourge RC, Feldman J, Frost AE, Galie N, et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation. 2013;127:1128\u201338.","DOI":"10.1161\/CIRCULATIONAHA.112.000765"},{"key":"9881_CR6","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.healun.2007.01.022","volume":"26","author":"RF Johnson","year":"2007","unstructured":"Johnson RF, Loyd JE, Mullican AL, Fink CA, Robbins IM. Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension. J Heart Lung Transplant. 2007;26:363\u20139.","journal-title":"J Heart Lung Transplant"},{"key":"9881_CR7","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/S0012-3692(16)48713-1","volume":"124","author":"NH Kim","year":"2003","unstructured":"Kim NH, Channick RN, Rubin LJ. Successful withdrawal of long-term epoprostenol therapy for pulmonary arterial hypertension. Chest. 2003;124:1612\u20135.","journal-title":"Chest"},{"key":"9881_CR8","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1161\/01.CIR.0000029100.82385.58","volume":"106","author":"VV McLaughlin","year":"2002","unstructured":"McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation. 2002;106:1477\u201382.","journal-title":"Circulation"},{"key":"9881_CR9","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0735-1097(02)02012-0","volume":"40","author":"O Sitbon","year":"2002","unstructured":"Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Herve P, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002;40:780\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"9881_CR10","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1161\/CIRCULATIONAHA.104.488486","volume":"111","author":"O Sitbon","year":"2005","unstructured":"Sitbon O, Humbert M, Jais X, Ioos V, Hamid AM, Provencher S, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005;111:3105\u201311.","journal-title":"Circulation"},{"issue":"Suppl. 56","key":"9881_CR11","first-page":"583s","volume":"40","author":"M Hoeper","year":"2012","unstructured":"Hoeper M, Barst R, Gali\u00e9 N, Hassoun P, Morrell N, Peacock A, et al. Long-term safety and efficacy of imatinib in pulmonary arterial [abstract]. Eur Respir J. 2012;40(Suppl. 56):583s.","journal-title":"Eur Respir J"},{"key":"9881_CR12","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/thx.2006.064097","volume":"61","author":"R Souza","year":"2006","unstructured":"Souza R, Sitbon O, Parent F, Simonneau G, Humbert M. Long term imatinib treatment in pulmonary arterial hypertension. Thorax. 2006;61:736.","journal-title":"Thorax"},{"key":"9881_CR13","first-page":"203","volume":"11","author":"RO Achcar","year":"2006","unstructured":"Achcar RO, Yung GL, Saffer H, Cool CD, Voelkel NF, Yi ES. Morphologic changes in explanted lungs after prostacyclin therapy for pulmonary hypertension. Eur J Med Res. 2006;11:203\u20137.","journal-title":"Eur J Med Res"},{"key":"9881_CR14","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1378\/chest.09-2815","volume":"138","author":"S Rich","year":"2010","unstructured":"Rich S, Pogoriler J, Husain AN, Toth PT, Gomberg-Maitland M, Archer SL. Long-term effects of epoprostenol on the pulmonary vasculature in idiopathic pulmonary arterial hypertension. Chest. 2010;138:1234\u20139.","journal-title":"Chest"},{"issue":"Suppl. 55","key":"9881_CR15","first-page":"50s","volume":"38","author":"M Hoeper","year":"2011","unstructured":"Hoeper M, Barst R, Gali\u00e9 N, Hassoun P, Morrell N, Peacock A, et al. Imatinib in pulmonary arterial hypertension, a randomized, efficacy study (IMPRES) [abstract]. Eur Respir J. 2011;38(Suppl. 55):50s.","journal-title":"Eur Respir J"},{"key":"9881_CR16","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1161\/CIRCULATIONAHA.113.001460","volume":"127","author":"M Humbert","year":"2013","unstructured":"Humbert M. Impression, sunset. Circulation. 2013;127:1098\u2013100.","journal-title":"Circulation"},{"key":"9881_CR17","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1161\/CIRCULATIONAHA.111.079921","volume":"125","author":"D Montani","year":"2012","unstructured":"Montani D, Bergot E, Gunther S, Savale L, Bergeron A, Bourdin A, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation. 2012;125:2128\u201337.","journal-title":"Circulation"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-013-9881-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11096-013-9881-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-013-9881-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T19:14:40Z","timestamp":1553627680000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11096-013-9881-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,28]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["9881"],"URL":"https:\/\/doi.org\/10.1007\/s11096-013-9881-x","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,28]]}}}